Zacks Investment Management Abb Vie Inc. Transaction History

Zacks Investment Management

$9.31 Billion
Q1 2024

A detailed history of Zacks Investment Management transactions in Abb Vie Inc. stock. As of the latest transaction made, Zacks Investment Management holds 723,286 shares of ABBV stock, worth $119 Million. This represents 1.41% of its overall portfolio holdings.

Number of Shares

723,286

Previous 637,286 13.49%

Holding current value

$119 Million

Previous $98.8 Million 33.36%

% of portfolio

1.41%

Previous 1.22%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$159.82 - $182.1 $13.7 Million - $15.7 Million	86,000 Added 13.49%	723,286 $132 Million
Q4 2023 Feb 14, 2024	SELL	$137.6 - $154.97 $6.09 Million - $6.85 Million	-44,228 Reduced 6.49%	637,286 $98.8 Million
Q3 2023 Nov 14, 2023	BUY	$133.59 - $154.65 $220,557 - $255,327	1,651 Added 0.24%	681,514 $102 Million
Q2 2023 Aug 15, 2023	BUY	$132.51 - $164.9 $6.37 Million - $7.93 Million	48,091 Added 7.61%	679,863 $91.6 Million
Q2 2023 Aug 14, 2023	SELL	$132.51 - $164.9 $5.3 Million - $6.6 Million	-40,010 Reduced 5.96%	631,772 $85.1 Million

Q1 2023 May 15, 2023	BUY	$144.61 - $166.54 $2.84 Million - $3.27 Million	19,647 Added 3.01%	671,782 $107 Million
Q4 2022 Feb 14, 2023	BUY	$138.31 - $165.87 $4 Million - $4.8 Million	28,952 Added 4.65%	652,135 $105 Million
Q3 2022 Nov 14, 2022	SELL	$134.21 - $153.93 $5 Million - $5.74 Million	-37,266 Reduced 5.64%	623,183 $83.6 Million
Q2 2022 Aug 15, 2022	BUY	$137.62 - $174.96 $5.05 Million - $6.42 Million	36,715 Added 5.89%	660,449 $101 Million
Q1 2022 May 13, 2022	BUY	$131.98 - $163.75 $3.23 Million - $4 Million	24,438 Added 4.08%	623,734 $101 Million
Q4 2021 Feb 15, 2022	BUY	$107.43 - $135.93 $4.86 Million - $6.15 Million	45,257 Added 8.17%	599,296 $81.1 Million
Q3 2021 Nov 15, 2021	BUY	$106.4 - $120.78 $2.42 Million - $2.75 Million	22,781 Added 4.29%	554,039 $59.8 Million
Q2 2021 Aug 16, 2021	BUY	$105.21 - $117.21 $1.24 Million - $1.38 Million	11,757 Added 2.26%	531,258 $59.8 Million
Q1 2021 May 17, 2021	SELL	$102.3 - $112.62 $1.6 Million - $1.77 Million	-15,682 Reduced 2.93%	519,501 $56.2 Million
Q4 2020 Feb 16, 2021	SELL	$80.49 - $108.67 $2.1 Million - $2.84 Million	-26,131 Reduced 4.66%	535,183 $57.3 Million
Q3 2020 Nov 16, 2020	SELL	$85.91 - $100.83 $1.85 Million - $2.17 Million	-21,527 Reduced 3.69%	561,314 $49.2 Million
Q2 2020 Aug 14, 2020	BUY	$73.37 - $98.18 $8.66 Million - $11.6 Million	118,031 Added 25.39%	582,841 $57.2 Million
Q1 2020 May 15, 2020	BUY	$64.5 - $97.79 $1.2 Million - $1.81 Million	18,537 Added 4.15%	464,810 $35.4 Million
Q4 2019 Feb 14, 2020	BUY	$72.13 - $90.25 $259,235 - $324,358	3,594 Added 0.81%	446,273 $39.5 Million
Q3 2019 Nov 14, 2019	BUY	$62.98 - $75.72 $657,511 - $790,516	10,440 Added 2.42%	442,679 $33.5 Million
Q2 2019 Aug 14, 2019	BUY	$65.7 - $83.98 $1.34 Million - $1.71 Million	20,378 Added 4.95%	432,239 $31.4 Million
Q1 2019 May 15, 2019	SELL	$77.14 - $90.79 $335,636 - $395,027	-4,351 Reduced 1.05%	411,861 $33.2 Million
Q4 2018 Feb 14, 2019	SELL	$77.85 - $96.01 $555,849 - $685,511	-7,140 Reduced 1.69%	416,212 $38.4 Million
Q3 2018 Nov 14, 2018	SELL	$88.91 - $98.84 $104,024 - $115,642	-1,170 Reduced 0.28%	423,352 $40 Million
Q2 2018 Aug 14, 2018	BUY	$89.78 - $106.23 $442,525 - $523,607	4,929 Added 1.17%	424,522 $39.3 Million
Q1 2018 May 14, 2018	SELL	$92.01 - $123.21 $15.3 Million - $20.5 Million	-166,381 Reduced 28.39%	419,593 $39.7 Million
Q4 2017 Feb 14, 2018	BUY	$89.56 - $98.21 $652,175 - $715,165	7,282 Added 1.26%	585,974 $56.7 Million
Q3 2017 Nov 14, 2017	BUY	$69.85 - $89.22 $40.4 Million - $51.6 Million	578,692	578,692 $51.4 Million

Others Institutions Holding ABBV

# of Institutions

3,653

Shares Held

1.24B

Call Options Held

15.5M

Put Options Held

11.6M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $290B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Zacks Investment Management, based on Form 13F filings with the SEC.

News

Stay updated on Zacks Investment Management with notifications on news.

Account

Zacks Investment Management Abb Vie Inc. Transaction History